전일 마감가:
$1.42
열려 있는:
$1.45
하루 거래량:
8.91M
Relative Volume:
0.71
시가총액:
$949.45M
수익:
$196.12M
순이익/손실:
$-69.59M
주가수익비율:
-14.19
EPS:
-0.1043
순현금흐름:
$-126.13M
1주 성능:
+2.78%
1개월 성능:
+12.12%
6개월 성능:
+7.25%
1년 성능:
+17.46%
제론 Stock (GERN) Company Profile
명칭
Geron Corp
전화
(650) 473-7700
주소
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
GERN
Geron Corp
|
1.48 | 910.96M | 196.12M | -69.59M | -126.13M | -0.1043 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
제론 Stock (GERN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-05-08 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 개시 | Leerink Partners | Outperform |
| 2024-04-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | 개시 | TD Cowen | Buy |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2023-09-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-28 | 개시 | Goldman | Neutral |
| 2022-10-28 | 개시 | Wedbush | Outperform |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2021-11-02 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 재개 | B. Riley Securities | Buy |
| 2020-08-03 | 개시 | Stifel | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-09-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-04-09 | 업그레이드 | Needham | Hold → Buy |
| 2019-01-31 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | 재확인 | FBR & Co. | Outperform |
| 2016-09-13 | 재확인 | FBR Capital | Outperform |
| 2015-12-07 | 재확인 | Piper Jaffray | Overweight |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-06-12 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-03-12 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2013-12-10 | 재확인 | MLV & Co | Buy |
| 2013-12-10 | 업그레이드 | Needham | Hold → Buy |
| 2013-11-08 | 재확인 | MLV & Co | Buy |
| 2013-10-16 | 개시 | MLV & Co | Buy |
| 2012-08-30 | 개시 | Stifel Nicolaus | Buy |
| 2012-06-28 | 개시 | Needham | Hold |
모두보기
제론 주식(GERN)의 최신 뉴스
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
GERN|Geron Corp|Price:1.420|Chg%:-0.030 - TradingKey
Geron Corp (GERN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron Corporation (GERN) stock price, news, quote and history - Yahoo Finance UK
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Five New Geron Hires Receive Options at $1.44 Per Share - Stock Titan
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 - Yahoo Finance
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron's New Business Chief Gets Option on 1.7M Shares - Stock Titan
Geron Corporation Grants Inducement Stock Options to New HiresEstimate Accuracy - dars.gov.et
Geron (GERN) Grants Inducement Stock Options to New Employees - Yahoo Finance
Geron appoints Chinmaya Rath as chief business officer - Investing.com
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer - GlobeNewswire
Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth - Stock Titan
ETFs Investing in Geron Corporation Stocks - TradingView
Geron stock leans on its myelofibrosis story - ad-hoc-news.de
Form 4 Geron Corporation For: 1 July By Investing.com - Investing.com Canada
Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees - Stock Titan
Geron Corporation (GERN) Shows Modest Bounce as Key Support HoldsOBV Breakout - dars.gov.et
GERN Forecast — Price Target — Prediction for 2027 - TradingView
Geron (GERN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Geron Corporation (GERN) Declines 1.5%, Nears Key Support at $1.25Cumulative Volume - dars.gov.et
GERON CORP (GERN) Stock Chart - ChartMill
GERN Stock Steadies As Geron Builds Commercial Momentum - StocksToTrade
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Geron Corp (GERN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Geron Corp (GERN) Institutional Confidence - TradingKey
Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GERN Stock Builds Momentum On Strong RYTELO Data - StocksToTrade
GERN Stock Steadies As Real‑World RYTELO Data Fuel Bullish Buzz - timothysykes.com
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - Ad-hoc-news.de
GERN: RYTELO’s expanding use and strong clinical data drive steady growth and future pipeline potential - TradingView
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp stock (US3741631036): Focus on valuation as short interest eases - AD HOC NEWS
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
Geron gets FDA nod for RYTELO in MDS, aims $220-240M revenue by 2026 despite slow start - Pluang
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN) - ChartMill
Geron Corporation (GERN) Slips 0.79%, Approaches Key Support LevelTriple EMA - dars.gov.et
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
제론 (GERN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):